In summary, our study identified ELOVL2 as the potential effective target for RPLS, and patients with LMS2 tumor indicated an immune-excluded phenotype might benefit more from small molecule inhibition targerted ELOVL2. This evidence concerns the gene ELOVL2 and neoplasm.